<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693430</url>
  </required_header>
  <id_info>
    <org_study_id>NN9536-4378</org_study_id>
    <secondary_id>2017-003726-32</secondary_id>
    <secondary_id>U1111-1202-1740</secondary_id>
    <nct_id>NCT03693430</nct_id>
  </id_info>
  <brief_title>Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity</brief_title>
  <acronym>STEP 5</acronym>
  <official_title>Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the change in body weight from the start to the end of the study.
      Researchers will compare the weight loss in people taking semaglutide (a new medicine) to
      people taking &quot;dummy&quot; medicine. In addition to taking the medicine, participants will also
      have talks with study staff about healthy food choices, how the participant can be more
      physically active and what participants can do to lose weight. Participants will either get
      semaglutide or &quot;dummy&quot; medicine - which treatment the participant gets is decided by chance.
      Participants will need to take 1 injection once a week. The study medicine is injected with a
      thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about
      2 years. The participants will have 19 clinic visits and 15 phone calls with the study
      doctor.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 5, 2018</start_date>
  <completion_date type="Anticipated">March 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 29, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects who achieve (yes/no): body weight reduction more than or equal to 5%</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Number of subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects who achieve (yes/no): body weight reduction more than or equal to 10%</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Number of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects who achieve (yes/no): body weight reduction more than or equal to 15%</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Number of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body mass index (BMI)</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin A1c (HbA1c)</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in mmol/mol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum insulin</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in micro IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high density lipoprotein (HDL) cholesterol</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in low density lipoprotein (LDL) cholesterol</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in very low density lipoprotein (VLDL) cholesterol</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in free fatty acids</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglycerides</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high sensitivity C-Reactive Protein</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Measured in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Measured in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects who achieve (yes/no): body weight reduction more than or equal to 5%</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Number of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects who achieve (yes/no): body weight reduction more than or equal to 10%</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Number of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects who achieve (yes/no): body weight reduction more than or equal to 15%</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Number of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Week 0, week 111</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events (SAEs)</measure>
    <time_frame>Week 0, week 111</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in amylase</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipase</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in calcitonin</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Measured in ng/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive semaglutide 2.4 mg during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo (semaglutide) during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks</description>
    <arm_group_label>Semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Semaglutide)</intervention_name>
    <description>S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age more than or equal to 18 years at the time of signing informed
             consent

          -  Body mass index (BMI) more than or equal to 30 kg/m^2 or more than or equal to 27
             kg/m^2 with the presence of at least one of the following weight-related comorbidities
             (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or
             cardiovascular disease

          -  History of at least one self-reported unsuccessful dietary effort to lose body weight

        Exclusion criteria:

          -  HbA1c more than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory
             at screening

          -  A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before
             screening irrespective of medical records
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3Z 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1G 1A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4P 1P2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4N 2W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1132</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1152</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Komarom</city>
        <zip>2900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Szekszárd</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Alcorcón</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Almeria</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S, Wilding JPH, Rubino D. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020 Jun;28(6):1050-1061. doi: 10.1002/oby.22794.</citation>
    <PMID>32441473</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

